EUVIMEDEUVIMED entdecken
Fallbericht

P-12: Teplizumab infusion during intensive endurance training in a 15-year-old competitive cyclist with stage 2 type 1 diabetes: a case report

J Mirza, E Teske, C Tekampe, K Moenkemoeller, M Weiss

Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)

DOI: 10.1159/hrp/adaag020.073 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von J Mirza und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Teplizumab approved by the EMA on January 8, 2026, is the first immunomodulatory therapy for delaying progression from stage 2 to stage 3 type 1 diabetes (T1D). Strenuous exercise during and after infusion with biologics is discussed controversially, yet real world data on safety during intensive athletic training are lacking. This is particularly relevant for young competitive athletes diagnosed with stage 2 T1D, as the window for beginning therapy is often limited.

Objectives

To report the safety and feasibility of completing the 14-day teplizumab infusion protocol while maintaining intensive endurance training and high-carbohydrate diet in a competitive adolescent cyclist.

Methods

A 15-year-old male competitive cyclist (height 184 cm, weight 62 kg) with Hashimoto thyroiditis (diagnosed 2023, treated with thiamazole 2.5 mg) was identified with stage 2 T1D in September 2025 (GADA+, IA-2A+, IAA-, ZnT8-); HbA1c 6.5%; C-peptide 2.1 ng/ml). The HbA1c level decreased to 5.9% in January. The patient developed an influenza-like-illness in February, and at the initiation of therapy in March, the HbA1c had increased to 6.3% and C-peptide declined to 1.1 ng/ml. He received the standard 14-day teplizumab protocol as inpatient. Each morning, he completed 2 hours of intensive cycling training before afternoon infusion to maintain his physical performance. Continuous glucose monitoring (CGM) was performed throughout (Fig.1).

Results

The patient completed all 14 infusions without interruption. CGM showed time in range of 89% with no hypoglycaemia during training sessions. Lymphocyte nadir was 9% with rapid recovery. No relevant transaminase elevation or other adverse events occurred. Training intensity was maintained throughout hospitalization.

Conclusions

This case suggests that intensive endurance training may be safely continued during teplizumab infusion in adolescent athletes with appropriate monitoring. Larger studies are needed to confirm these findings.

Zitieren

APA

Mirza, J., Teske, E., Tekampe, C., Moenkemoeller, K., & Weiss, M. (2026). P-12: Teplizumab infusion during intensive endurance training in a 15-year-old competitive cyclist with stage 2 type 1 diabetes: a case report. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.073

Vancouver

Mirza J, Teske E, Tekampe C, Moenkemoeller K, Weiss M. P-12: Teplizumab infusion during intensive endurance training in a 15-year-old competitive cyclist with stage 2 type 1 diabetes: a case report. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.073

BibTeX
@article{Mirza2026,
  author = {Mirza, J and Teske, E and Tekampe, C and Moenkemoeller, K and Weiss, M},
  title = {P-12: Teplizumab infusion during intensive endurance training in a 15-year-old competitive cyclist with stage 2 type 1 diabetes: a case report},
  journal = {Hormone Research in Paediatrics},
  year = {2026},
  volume = {99},
  number = {Supplement_4},
  doi = {10.1159/hrp/adaag020.073}
}
Kostenlos starten →